Welcome to the 2024 Annual Meeting of Editas Medicine Stockholders. I would now like to introduce Emma Reeve, Chair of the Board.
Good morning, and welcome to the 2024 Annual Meeting of Stockholders of Editas Medicine. I am Emma Reeve, Chair of the Board, and I will be presiding over this meeting. At this time, I call the meeting to order. We're pleased to have everyone join this live webcast of our annual meeting, which is being held in an all-virtual format. We've designed this meeting to provide stockholders the same rights and opportunities to participate as they would have had at an in-person meeting.
Before we get to the formal business of the meeting, I'd like to make some introductions. Present at the meeting today are Meeta Chatterjee and Andrew Hirsch, each a nominee for director, as well as Bernadette Connaughton, Jessica Hopfield, Elliott Levy, David Scadden, and Akshay Vaishnaw, each a director of Editas Medicine. In addition, I'm pleased to be joined by our President and Chief Executive Officer, Gilmore O'Neill, who's also a nominee for director, and other members of the senior management with us today.
Linnea Aspesi, our Chief People Officer, Linda C. Burkly, our Chief Scientific Officer, Caren Deardorf, our Chief Commercial and Strategy Officer, Erick Lucera, our Chief Financial Officer, Baisong Mei, our Chief Medical Officer, Charlene Stern, our General Counsel, and Greg Whitehead, our Chief Technical and Quality Officer. I'd also like to introduce Jennifer Hillenmeyer, a representative from Ernst & Young, our independent registered public accounting firm, and Terry Hassett, who will be serving as our Inspector of Election. After we complete the formal part of the meeting, we'll take questions.
In light of the company's upcoming clinical updates on the Phase I/ II/ III RUBY trial of reni-cel for sickle cell disease and the Phase I/ II EdiTHAL trial of reni-cel for transfusion-dependent beta thalassemia, which are to be provided at the European Hematology Association Congress in June, we will not be conducting a management presentation at this meeting. We do hope that you can join us for the clinical updates.
In order to conduct an orderly meeting, I call your attention to the rules of conduct posted on the virtual meeting website, which include information about participating in the meeting, including asking questions. I've received an affidavit from the company's proxy solicitor, Broadridge Financial Solutions, certifying that the notice of the annual meeting and proxy statement were sent to all stockholders of record as of April 2, 2024. This affidavit is available for inspection by any stockholder.
Our first order of business at this meeting is to determine whether the shares represented at this meeting, either in person via this virtual meeting or by proxy, are sufficient to constitute a quorum for the purpose of transacting business. The Inspector of Election has informed me that there are present at this meeting, either in person or by proxy, a majority of outstanding shares of common stock entitled to vote. Therefore, I declare that a quorum exists.
Turning now to the items to be voted on at this meeting. As indicated in the notice of meeting and accompanying documents that were sent to the stockholders, the first matter to be voted on is the election of three Class II directors to serve until the 2027 annual meeting of stockholders and until their successors duly elected and qualified.
The three nominees for election are Meeta Chatterjee, Andrew Hirsch, and Gilmore O'Neill. The next matter to be voted upon is the advisory vote to approve named executive officer compensation. The proxy statement for this meeting contained the text of the resolution that stockholders are asked to approve. The final matter to be voted on is the ratification of the selection of Ernst & Young LLP as the company's registered public accounting firm for the fiscal year ending December 31st, 2024.
If there are any questions on the proposals, they may be submitted on the virtual meeting website. If you're asking a question, please also include your name and affiliation to the company. We'll briefly pause now to allow the submission of any questions on the proposals. Seeing no questions about the proposals, we'll move on to voting on the proposals.
I hereby declare that the polls are now open for each matter to be voted upon today. If you've not yet voted, or if you previously voted by proxy and wish to change your vote, you may vote by clicking the "Vote Here" button on the virtual meeting website and following the instructions there. We'll pause briefly again to allow stockholders to vote. Now that everyone has had an opportunity to vote, the business items on the agenda for this meeting are complete, and the polls are now closed.
Terry Hassett, the Inspector of Election, will prepare a final report that will be filed with the minutes of this meeting. Based on the preliminary results, each of the nominees for director has been elected as a Class II director.
The advisory resolution approving named executive officer compensation has been approved, and the appointment of Ernst & Young has been ratified. The final vote results will be included in the Form 8-K that will be filed within four business days after this meeting. As there's no further business to come before the meeting, I declare the formal part of this meeting adjourned. At this time, the members of the company's management will answer any appropriate questions from the stockholders, and I'd like to ask Charlene Stern to help coordinate and announce questions.
Before we begin the Q&A session, I would like to note that various remarks that we may make about future expectations, plans, and prospects for the company constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC and other, and in other filings that the company may make with the SEC in the future. In addition, these forward-looking statements represent the company's expectations only as of today. While the company may elect to update these forward-looking statements, it specifically disclaims any obligation to do so.
Any forward-looking statements should not be relied upon as representing the company's estimates or views as of any date subsequent to today. We will now begin the Q&A session. You can ask a question by submitting it in the Q&A section of your web console. Please submit questions now. There are no questions at this time. Emma, I turn the call back over to you.
Thank you again for your continued dedication to the company. The Annual Stockholder Meeting for Editas Medicine has now come to an end. Thank you for attending. You may now disconnect.
This concludes today's meeting. Thank you all for joining, and you may now disconnect.